Drug
Povetacicept clinical trials
Also written ALPN-303.
- studies test it
- 9
- open now
- 4
- in phase 3
- 4
- first study started
- 2021
Keep track of what changes. Save the povetacicept studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
9 studies that test it; most in 2026 (3)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 4
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 0
Vertex Pharmaceuticals Incorporated (5) · Alpine Immune Sciences, Inc. (2) · Alpine Immune Sciences Inc, A Subsidiary of Vertex (2)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses povetacicept is read from its arms, and is right about nine times in ten.
Testing it · 9
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via Prefilled SyringeNot yet recruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT07890909Written as Povetacicept
- A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A NephropathyEnrolling by invitationPhase 3Vertex Pharmaceuticals IncorporatedNCT07807995Written as Povetacicept
- Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)RecruitingPhase 2/3Vertex Pharmaceuticals IncorporatedNCT07204275Written as Povetacicept
- A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia GravisRecruitingPhase 2Vertex Pharmaceuticals IncorporatedNCT07501702Written as Povetacicept
- An Open-label Study of Povetacicept in Autoantibody-Associated Glomerular DiseasesActive, not recruitingPhase 1/2Alpine Immune Sciences, Inc.NCT05732402Written as Povetacicept
- An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4)CompletedPhase 1/2Alpine Immune Sciences Inc, A Subsidiary of VertexNCT05757570Written as Povetacicept
- Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN)Active, not recruitingPhase 3Alpine Immune Sciences Inc, A Subsidiary of VertexNCT06564142Written as Povetacicept
- A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept PresentationsCompletedPhase 1Vertex Pharmaceuticals IncorporatedNCT07010406Written as Povetacicept
- A Study of ALPN-303 in Adult Healthy VolunteersCompletedPhase 1Alpine Immune Sciences, Inc.NCT05034484Written as ALPN-303
Codes
What other systems call povetacicept · ClinicalTrials.gg INT016470
- UNII (FDA) EN2U82XV65POVETACICEPTOne source FDA
- NCI Thesaurus C190436PovetaciceptOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | EN2U82XV65 | POVETACICEPT | One source FDA |
| NCI Thesaurus | C190436 | Povetacicept | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.